Lakewood-Amedex Biotherapeutics Files S-1/A Amendment

Ticker: LABT · Form: S-1/A · Filed: Apr 6, 2026 · CIK: 0002079272

Sentiment: neutral

Topics: securities-offering, registration-statement, amendment

TL;DR

Lakewood-Amedex Biotherapeutics filed an S-1/A amendment on 4/6/2026 for a securities registration.

AI Summary

Lakewood-Amedex Biotherapeutics Inc. filed an S-1/A amendment on April 6, 2026, to register securities. The filing includes various exhibits such as consents of independent registered public accounting firms and numerous graphic files, likely containing financial data and charts. The company is based in University Park, Florida.

Why It Matters

This S-1/A filing indicates Lakewood-Amedex Biotherapeutics is actively pursuing a securities offering, which could lead to new capital for the company's operations or expansion.

Risk Assessment

Risk Level: medium — S-1/A filings are typically associated with new securities offerings, which carry inherent risks related to market reception and company performance.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

The S-1/A filing is an amendment to a registration statement for the registration of securities under the Securities Act of 1933.

When was this amendment filed?

This amendment was filed on April 6, 2026.

What is the company's CIK number?

The CIK number for Lakewood-Amedex Biotherapeutics Inc. is 0002079272.

Where is Lakewood-Amedex Biotherapeutics Inc. located?

The company's mailing and business address is 8031 Cooper Creek Blvd., Suite 103, University Park, FL 34201.

What types of exhibits are included in this filing?

The filing includes consents of independent registered public accounting firms and numerous graphic files (images and charts).

Filing Stats: 4,231 words · 17 min read · ~14 pages · Grade level 15.2 · Accepted 2026-04-06 11:38:04

Key Financial Figures

Filing Documents

RISK FACTORS

RISK FACTORS   12

USE OF PROCEEDS

USE OF PROCEEDS   41 DIVIDEND POLICY   42 CAPITALIZATION   43 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   45

BUSINESS

BUSINESS   57 MANAGEMENT   100 EXECUTIVE AND DIRECTOR COMPENSATION   106 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS   112 PRINCIPAL AND REGISTERED STOCKHOLDERS   114

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK   117 PLAN OF DISTRIBUTION   121 SHARES ELIGIBLE FOR FUTURE SALE   124 SALE PRICE HISTORY OF COMMON STOCK   127 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS   128 LEGAL MATTERS   134 EXPERTS   134 WHERE YOU CAN FIND MORE INFORMATION   134 INDEX TO FINANCIAL STATEMENTS   F-1 i Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward -looking statements.” All statements other than statements of historical facts contained in this prospectus may be forward -looking statements. These forward -looking statements can generally be identified by the use of forward -looking terminology, including the terms “believes,” “estimates,” “continues,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” “would” or “should” or, in each case, their negative or other variations or comparable terminology. They appear in a number of places throughout this prospectus, and include statements regarding our intentions, beliefs, or current expectations concerning, among other things, our results of operations, financial condition, liquidity, prospects, growth, strategies, future acquisitions, and the industry in which we operate. By their nature, forward -looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We believe that these risks and uncertainties include, but a

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing